Last reviewed · How we verify

NCT06785714

Colorectal Cancer Screening in Xinxiang City

Completed Last updated 21 January 2025
What this trial tests

trial in Colorectal Cancer in 25,000 participants. Completed in 15 January 2025.

Timeline
1 September 2024
Primary endpoint
15 January 2025
15 January 2025

Quick facts

Lead sponsorThe First Affiliated Hospital of Xinxiang Medical College
StatusCompleted
Study typeOBSERVATIONAL
Enrollment25,000
Start date1 September 2024
Primary completion15 January 2025
Estimated completion15 January 2025
Sites1 location across China

Conditions studied

Sponsor

The First Affiliated Hospital of Xinxiang Medical College

Who can join

Adults 45 to 74, any sex, with Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this study is to evaluate the sensitivity of the fecal protein dual-index test reagent for the detection of colorectal cancer (CRC).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Colorectal Cancer

Currently open trials in the same condition.

Other The First Affiliated Hospital of Xinxiang Medical College trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06785714.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing